STOCK TITAN

Equity grants increase Corbus (CRBP) director Ben Yong’s holdings

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Corbus Pharmaceuticals director Ben Yong received new equity awards as part of his compensation. On May 19, he was granted 3,800 restricted stock units that will convert into common shares after they vest in full one year from the grant date.

He also received stock options for 12,300 shares of common stock at an exercise price of $9.15 per share, which will also vest 100% after one year under the company’s 2024 Equity Compensation Plan. Following these awards, he directly holds 11,383 shares of common stock, including previously reported unvested RSUs.

Positive

  • None.

Negative

  • None.
Insider Ben Yong
Role null
Type Security Shares Price Value
Grant/Award Stock options (right to buy) 12,300 $0.00 --
Grant/Award Common Stock, par value $0.0001 per share 3,800 $0.00 --
Holdings After Transaction: Stock options (right to buy) — 12,300 shares (Direct, null); Common Stock, par value $0.0001 per share — 11,383 shares (Direct, null)
Footnotes (1)
  1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
RSUs granted 3,800 units Restricted stock units granted on May 19, 2026
RSU vesting 100% after 1 year Vests on one-year anniversary of grant date
Options granted 12,300 options Stock options awarded on May 19, 2026
Option exercise price $9.15 per share Exercise price for 12,300 stock options
Shares held after transaction 11,383 shares Direct common stock holdings after awards
Previously unvested RSUs 8,600 units Unvested RSUs from prior grants included in total
restricted stock units ("RSUs") financial
"On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
vesting schedule financial
"This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported"
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
Equity Compensation Plan financial
"The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan"
A plan by which a company gives employees, directors or contractors ownership or the right to buy ownership in the company through stock, options or similar awards — think of promising slices of the company pie as part of someone's pay. It matters to investors because these awards can change the number of shares outstanding, affect reported profits and influence management’s decisions; large or generous plans can dilute existing holders and alter incentives over time.
stock options (right to buy) financial
"Stock options (right to buy)"
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ben Yong

(Last)(First)(Middle)
C/O CORBUS PHARMACEUTICALS HOLDINGS, INC
500 RIVER RIDGE DRIVE

(Street)
NORWOOD MASSACHUSETTS 02062

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Corbus Pharmaceuticals Holdings, Inc. [ CRBP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, par value $0.0001 per share05/19/2026A3,800(1)A$011,383(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock options (right to buy)$9.1505/19/2026A12,300 (3)05/19/2026Common Stock12,300$012,300D
Explanation of Responses:
1. On May 19, 2026, 3,800 restricted stock units ("RSUs") were granted, which will be settled in shares of common stock, par value $0.0001. The RSUs will vest 100% on the one-year anniversary from the date of grant.
2. This amount includes 8,600 unvested RSUs subject to each grant's vesting schedule as previously reported.
3. The option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. The option will vest 100% on the one-year anniversary from the date of grant.
/s/ Meghan Houghton, attorney-in-fact for Yong Ben05/21/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did Corbus (CRBP) director Ben Yong report?

Ben Yong reported receiving equity awards, not open-market trades. He was granted 3,800 restricted stock units and stock options for 12,300 shares, both vesting in one year, increasing his direct equity-based exposure to Corbus Pharmaceuticals.

How many Corbus (CRBP) restricted stock units did Ben Yong receive?

Ben Yong received 3,800 restricted stock units from Corbus Pharmaceuticals. These RSUs will settle in common stock and vest 100% on the one-year anniversary of the May 19, 2026 grant date, aligning his compensation with future company performance.

What stock options were granted to Corbus (CRBP) director Ben Yong?

Ben Yong was granted options covering 12,300 shares of Corbus common stock. The options have a $9.15 exercise price and were issued under the 2024 Equity Compensation Plan, vesting in full one year after the grant date, subject to plan terms.

How many Corbus (CRBP) shares does Ben Yong hold after these grants?

After the May 19, 2026 awards, Ben Yong directly holds 11,383 shares of Corbus common stock. This figure includes previously reported unvested restricted stock units that remain subject to their individual vesting schedules under prior grants.

Are Ben Yong’s Corbus (CRBP) equity awards immediately vested or deferred?

Both new awards are deferred through time-based vesting. The 3,800 RSUs and 12,300 stock options will each vest 100% on the one-year anniversary of the May 19, 2026 grant date, assuming continued service and satisfaction of plan conditions.